The legacy of Sildenafil offers a intricate case study for investors eyeing pharma. While initial sales were remarkable, present patent expiry and the emergence of alternative versions have severely impacted earnings. https://mattieofhz973532.blogoxo.com/41419466/the-blue-pill-and-big-pharma-a-precarious-stake